Back to Search Start Over

Delivery cost of the first public sector introduction of typhoid conjugate vaccine in Navi Mumbai, India.

Authors :
Dayoung Song
Sarah W Pallas
Rahul Shimpi
N Ramaswamy
Pradeep Haldar
Pauline Harvey
Pankaj Bhatnagar
Arun Katkar
Niniya Jayaprasad
Abhishek Kunwar
Sunil Bahl
Win Morgan
Raymond Hutubessy
Kashmira Date
Vittal Mogasale
Source :
PLOS Global Public Health, Vol 3, Iss 1, p e0001396 (2023)
Publication Year :
2023
Publisher :
Public Library of Science (PLoS), 2023.

Abstract

Navi Mumbai Municipal Corporation (NMMC), a local government in Mumbai, India, implemented the first public sector TCV campaign in 2018. This study estimated the delivery costs of this TCV campaign using a Microsoft Excel-based tool based on a micro-costing approach from the government (NMMC) perspective. The campaign's financial (direct expenditures) and economic costs (financial costs plus the monetized value of additional donated or existing items) incremental to the existing immunization program were collected. The data collection methods involved consultations with NMMC staff, reviews of financial and programmatic records of NMMC and the World Health Organization (WHO), and interviews with the health staff of sampled urban health posts (UHPs). Three UHPs were purposively sampled, representing the three dominant residence types in the catchment area: high-rise, slum, and mixed (high-rise and slum) areas. The high-rise area UHP had lower vaccination coverage (47%) compared with the mixed area (71%) and slum area UHPs (76%). The financial cost of vaccine and vaccination supplies (syringes, safety boxes) was $1.87 per dose, and the economic cost was $2.96 per dose in 2018 US dollars. Excluding the vaccine and vaccination supplies cost, the financial delivery cost across the 3 UHPs ranged from $0.37 to $0.53 per dose, and the economic delivery cost ranged from $1.37 to $3.98 per dose, with the highest delivery costs per dose in the high-rise areas. Across all 11 UHPs included in the campaign, the weighted average financial delivery cost was $0.38 per dose, and the economic delivery cost was $1.49 per dose. WHO has recommended the programmatic use of TCV in typhoid-endemic countries, and Gavi has included TCV in its vaccine portfolio. This first costing study of large-scale TCV introduction within a public sector immunization program provides empirical evidence for policymakers, stakeholders, and future vaccine campaign planning.

Details

Language :
English
ISSN :
27673375
Volume :
3
Issue :
1
Database :
Directory of Open Access Journals
Journal :
PLOS Global Public Health
Publication Type :
Academic Journal
Accession number :
edsdoj.86ec1a36485d81a0c472f92eab1a
Document Type :
article
Full Text :
https://doi.org/10.1371/journal.pgph.0001396